Cardiff Oncology, Inc. Common Stock
Symbol: CRDF (NASDAQ)
2.10
▲ (2.70%) 0.055
Company Description:
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
Key Stats
- Today's Open: $2.04
- Today's High: $2.105
- Today's Low: $2.045
- Today's Volume: 589.66K
- Yesterday Close: $2.04
- Yesterday High: $2.14
- Yesterday Low: $2.03
- Yesterday Volume: 707.94K
- Last Min Volume: 75
- Last Min High: $2.095
- Last Min Low: $2.095
- Last Min VWAP: $2.095
Company Profile
- Name: Cardiff Oncology, Inc. Common Stock
- Website: https://www.cardiffoncology.com
- Listed Date: 1997-05-22
- Location: SAN DIEGO, CA
- Market Status: Active
- CIK Number: 0001213037
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $135.71M
- Round Lot: 100
- Outstanding Shares: 66.53M
- Asset Type: CS
RECENT FILINGS FOR CRDF
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-28 | S-8 | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-07-31 | 4 | View |
| 2025-07-29 | 8-K | View |
| 2025-07-29 | 10-Q | View |
| 2025-07-29 | SCHEDULE 13G | View |
| 2025-07-08 | 3 | View |
| 2025-06-30 | 4 | View |
| 2025-06-30 | 4 | View |
| 2025-06-30 | 4 | View |
| 2025-06-27 | 4 | View |
| 2025-06-27 | 4 | View |
| 2025-06-27 | 4 | View |
| 2025-06-26 | 8-K | View |
| 2025-06-17 | 8-K | View |
| 2025-05-13 | EFFECT | View |
| 2025-05-12 | CORRESP | View |
| 2025-05-08 | S-3/A | View |
| 2025-05-08 | 8-K | View |
| 2025-05-08 | 10-Q | View |
Latest News on CRDF